July 15-16, 2013 – Global Patenting Strategy and Practice (American Conference
Institute) – New
York, NY

July 15-19, 2013 – Patent Law Summer
Intensive (Benjamin N. Cardozo School of Law) – New York, NY

July 16, 2013 – FTC v. Actavis: Practical Implications of the Landmark
Supreme Court Decision (Law
Seminars International) – 3:00 to 4:00
pm (Eastern)

July
17, 2013 – European biotech patent law update (D
Young & Co) – 4:00 am, 7:00 am, 12:00 pm (EDT)

July 17,
2013 – The Myriad
Decision: Practical Implications for
Biotechnology Companies Protecting IP Assets (Law
Seminars International) – 3:00 to 4:00 pm (Eastern)

July 17-18, 2013 – Legal
and Regulatory Summit on Generic Drugs (American Conference
Institute) – New York, NY

July 22, 2013 – IP & Diagnostics Symposium (Biotechnology
Industry Organization) – Alexandria, VA

July 24, 2013 – AIA and Patent Prosecution: Navigating the
Ethical Grey Areas (Strafford) – 1:00 to 2:30 pm
(EDT)

July 28-30, 2013 – 2013 Annual Meeting & Conference (National Association of Patent Practitioners) – San
Diego, CA

July 30,
2013 – Are We Innovators, or Are We
Trolls: The Slippery Slope of Defining A Patent Troll (McDonnell
Boehnen Hulbert & Berghoff LLP) – 10:00 to 11:15 am (CT)

July 31 to August 2, 2013 – Advanced Patent Law Seminar (Chisum Patent Academy) – Seattle, WA

August 5-7, 2013 – Advanced Patent Law Seminar (Chisum Patent Academy) – Seattle, WA

August 8, 2013 – Analyzing and Adapting to the Supreme Court's
Myriad Ruling (Technology
Transfer Tactics) – 1:00 to 2:00 pm
(Eastern)

August 8-11,
2013 – 2013 Annual Meeting (American Bar
Association) – San Francisco, CA

August 21, 2013 – Inducement to Infringe in Hatch-Waxman Litigation: Lessons from Commil USA v. Cisco Systems and Bayer Schering v. Lupin for Pharma
Patents (Strafford) – 1:00 to 2:30 pm (EDT)

August
22, 2013 – What are the Implications of CLS
Bank Int'l v. Alice Corp. on Computer-Implemented Inventions? (McDonnell
Boehnen Hulbert & Berghoff LLP) – 10:00 to 11:15 am (CT)

September 17-18, 2013 – FDA Boot Camp (American Conference
Institute) – Boston, MA

September 18, 2013 – Conflicts in Patent Prosecution: Avoiding the
Ethical Pitfalls Minimizing Risks of Malpractice Liability and Ethics Sanctions (Strafford) – 1:00 to 2:30 pm (EDT)

***Patent Docs is a media partner of this conference or CLE

American Conference
Institute (ACI) will be holding the next session of its FDA Boot Camp
conference on September 17-18, 2013 in Boston, MA.  ACI faculty will help attendees:

• Master the basics
of the application and approval processes for drugs, biologics, and devices
• Comprehend the
structure of the FDA and the roles of the three major agency centers:  CDER, CBER, and CDHR
• Develop a
practical working knowledge of clinical trials for drugs and biologics and the
clearance process for devices
• Learn how devices
are classified, monitored, and regulated
• Appreciate the
complexities of pharmaceutical IP and the regulatory balance between brand name
and generic products
• Recognize the
pivotal role of labeling in the drug and biologics approval process
• See the
importance of cGMPs to the post-approval regulatory process
• Navigate the
protocols of adverse events monitoring, signal detection, product withdrawals,
and recalls

In particular,
ACI's faculty will offer presentations on the following topics:

• The Basics: Understanding and Working with
the FDA — Jurisdiction, Functions, Organization, and Operations
• The Nature of the Approval Process
• Understanding the Clinical Trial Process for
Drugs and Biologics
• Obtaining and Challenging Market Exclusivity
for Drug Products and Biologic Products: IP Protection, Data Exclusivity,
Trademark and Brand Protection, Hatch-Waxman, BPCIA, and More:
• Part 1 — Overview of Patent and Trademark
Issues
• Part 2 — Hatch-Waxman and BPCIA Overview
• Drugs and Biologics: Labeling
• cGMPs: Drugs and Biologics (Current Good
Manufacturing Practices)
• Adverse Events Monitoring, Pharmacovigilance
and Risk Management
• Medical Devices: Classifications, the
Essentials of the Premarket Review Process, and Post-Market Requirements and
Concerns
• Recall Guidance for Drugs, Biologics, and
Medical Devices: What You Need to Know

A pre-conference
workshop on the "Fundamentals of FDA Regulatory Law" and
"Resolving Ethical Challenges Encountered During the Drug Approval
Process" will be offered on September 16, 2013 from 1:00 to 5:00 pm.  The first part of the workshop will provide a
basic overview of FDA regulations and will prepare attendees for the in-depth
discussions that will take place throughout the conference, and explore ethical
issues that may arise in the context of communications with FDA on behalf of
clients.  The second part of the workshop
will explore ethical issues that may arise in the context of communications
with FDA on behalf of clients.

Two post-conference
master classes will be offered on September 18, 2013.  The first master class, entitled
"Hatch-Waxman and BPCIA: Overview of Biosimilars and Life Cycle Planning
for Drugs and Biologics," will provide an in-depth overview of biosimilars
as well as analyses of bioequivalence and exclusivities and their role in
patent and product life cycle management. 
The second master class, entitled "Post-Approval Marketing Guidance
and Preemption Protocols," will address issues that arise post-approval,
including advertising, promotion, and off-label promotion and enforcement, as
well as preemption fundamentals.

An agenda for the
conference can be found here.  A complete brochure for this conference,
including an agenda, detailed descriptions of conference sessions, list of
speakers, and registration form can be obtained here.

The registration
fee is $2,295 (conference alone), $2,895 (conference and workshop or conference
and one master class), or $3,295 (conference, workshop, and one master class).  Those registering by July 19, 2013 will
receive a $300 discount and those registering by August 16, 2013 will receive a
$200 discount.  Patent Docs readers who reference the discount code "PD
200" will receive $200 off the current price tier when registering.  Those interested in registering for the
conference can do so here,
by e-mailing CustomerService@AmericanConference.com, by calling 1-888-224-2480,
or by faxing a registration form to 1-877-927-1563.

Patent Docs is a media partner of ACI's FDA Boot Camp conference.

Law
Seminars International (LSI) will be offering a one-hour telebriefing on "The Myriad
Decision: Practical Implications for
Biotechnology Companies Protecting IP Assets" on July 17,
2013 from 3:00 to 4:00 pm (Eastern).  Dr.
Barbara R. Rudolph of Finnegan
Henderson Farabow Garrett & Dunner LLP will moderate a panel that
includes Jennifer L. Swize of Jones Day
and Courtenay C. Brinckerhoff of Foley
& Lardner LLP.  The panel will
discuss the Myriad decision and the possible implications for patent
procurement, patent litigation, the biotechnology industry, and the future of
medical research.  Among the topics to be
covered are:

•
Impact of the Myriad Decision on
patents for genetic research
•
How the decision distinguishes between natural and synthetic gene sequences
•
Legal and business implications for the biotech industry
•
New strategies for protecting DNA-based intellectual property moving forward

A
Q&A will follow the presentation and last for up to 30 minutes.

The
registration fee is $150 per caller and $100 for each additional person on the
same line who desires continuing education credit.  Those interested in registering for the
telebriefing, can do so here.

Strafford
will be offering a webinar/teleconference on "Inducement to Infringe in Hatch-Waxman Litigation: Lessons from Commil USA v. Cisco Systems and Bayer Schering v. Lupin for Pharma
Patents" on August 21, 2013 from 1:00 to 2:30 pm (EDT).  Thomas
L. Irving, Dr. David P. Frazier, and Robert F. Shaffer of Finnegan Henderson
Farabow Garrett & Dunner provide patent counsel with guidance on
claim and label language; to proactively coordinate patent, regulatory and
clinical personnel; and to maintain consistency between claims and likely or
actual label language throughout patent prosecution and label negotiation with
the FDA.  The webinar will review the
following questions:

•
What can be learned from the AstraZeneca v. Apotex, Bayer Schering v.
Lupin, and Commil USA v. Cisco Systems Inc. decisions?
•
What are the best approaches to maintain consistency between claims and likely
or actual label language?
•
What steps can be taken to maintain the coordination of patent, regulatory and
clinical personnel throughout the patent prosecution and label negotiation with
the FDA?

The
registration fee for the webinar is $297 ($362 for registration and CLE processing).  Those registering by July 26, 2013 will
receive a $50 discount.  Those interested
in registering for the webinar, can do so here.

D
Young & Co will be offering its next European biotech patent law update on July
17, 2013.  The 45-minute webinar will be
offered at three times: 4:00 am, 7:00 am, 12:00 pm (EDT). D Young & Co
European Patent Attorneys Robert Dempster and Simon O'Brien will provide an
essential update and live Q&A on EPO biotechnology case law.

While
there is no fee to participate, attendees must register in advance.  Those wishing to register can do so here.

McDonnell
Boehnen Hulbert & Berghoff LLP will be offering a live webinar entitled
"What are the Implications of CLS
Bank Int'l v. Alice Corp. on Computer-Implemented Inventions?" on August
22, 2013 from 10:00 am to 11:15 am (CT). 
MBHB attorney Rory P. Shea will cover the potential implications of the CLS
Bank decision on claims directed to computer-implemented inventions.  Topics to be covered include:

•
A review of the CLS Bank
decision and the takeaways from that decision
• A review of how courts are interpreting and
applying the CLS Bank decision since it was handed down
• A discussion of how the CLS Bank decision
may impact the prosecution and litigation of claims directed to
computer-implemented inventions going forward

While
there is no fee to participate, attendees must register in advance.  Those wishing to register can do so here.  CLE credit is pending for the states of California,
Georgia, Illinois, North Carolina, New Jersey, New York and Virginia.